Gyre Therapeutics, Inc. Deferred Revenue, Revenue Recognized
Gyre Therapeutics, Inc. (GYRE) reported Deferred Revenue, Revenue Recognized of $200.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2023-03-30
- Gyre Therapeutics, Inc. deferred revenue, revenue recognized for the quarter ending 2022-03-31 was $200.00K, a 75.00% decline year-over-year.
- Gyre Therapeutics, Inc. deferred revenue, revenue recognized for the quarter ending 2021-03-31 was $800.00K.
- Gyre Therapeutics, Inc. deferred revenue, revenue recognized for fiscal 2022 was $200.00K, a 90.00% decline from fiscal 2021.
- Gyre Therapeutics, Inc. deferred revenue, revenue recognized for fiscal 2021 was $2.00M.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2022-12-31 | $200.00K 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $200.00K 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $200.00K 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $200.00K 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $2.00M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $1.60M 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $1.30K 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $800.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |